BACKGROUND. Leukemic cells in 15 to 25 percent of patients with acute lymphoblastic leukemia (ALL) express myeloid antigens as well as lymphoid antigens (the latter reflecting B-cell or T-cell lineage). The relations of myeloid-antigen expression to other features of ALL and to prognosis have been controversial. METHODS. We analyzed clinical and laboratory features present at diagnosis in 236 consecutive cases of ALL in children. Immunophenotyping, including single- and dual-fluorescence analyses, was used to classify leukemic cells as B or T lymphoblasts and also to identify myeloid-antigen expression--the simultaneous expression of lymphoid-associated antigens and at least one of three myeloid-associated antigens (CD33, CD13, and CD14) on cells classified as L1 or L2 according to the French-American-British system. RESULTS. Forty-five of 185 patients with B-lineage ALL had myeloid-antigen expression, as did 8 of 41 patients with T-lineage ALL. In 10 patients, the lineage could not be determined. Myeloid-antigen expression was associated with L2 morphology (P less than 0.05), but it did not correlate with other prognostic features recognized previously. Multivariate analysis showed that myeloid-antigen expression was an important predictor of relapse in childhood ALL and the most significant prognostic factor statistically (P less than 0.0001). A white-cell count greater than or equal to 50 x 10(9) per liter at diagnosis was also an important and highly significant prognostic feature (P less than 0.001). After 40 months, the estimated disease-free survival for patients with ALL was 84 percent for those without myeloid-antigen expression and with a low white-cell count, 57 percent for those without myeloid-antigen expression and with a high white-cell count, 47 percent for those with myeloid-antigen expression and a low white-cell count, and 26 percent for those with myeloid-antigen expression and a high white-cell count (P less than 0.00001). CONCLUSIONS. Myeloid-antigen expression is an important independent predictor of a poor response to chemotherapy in childhood ALL.
Source Information
Division of Hematology/Oncology, Childrens Hospital Los Angeles.
This article has been cited by other articles:
Cox, C. V., Martin, H. M., Kearns, P. R., Virgo, P., Evely, R. S., Blair, A.
(2007). Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood
109: 674-682
[Abstract][Full Text]
Vitale, A., Guarini, A., Ariola, C., Mancini, M., Mecucci, C., Cuneo, A., Pane, F., Saglio, G., Cimino, G., Tafuri, A., Meloni, G., Fabbiano, F., Recchia, A., Kropp, M. G., Krampera, M., Cascavilla, N., Ferrara, F., Romano, A., Mazza, P., Fozza, C., Paoloni, F., Vignetti, M., Foa, R.
(2006). Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood
107: 473-479
[Abstract][Full Text]
Oki, Y., Kishi, Y., Kami, M., Fruchter, O., Valsecchi, M. G., Schrappe, M., Pui, C.-H.
(2000). Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Children. NEJM
343: 1043-1044
[Full Text]
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., Ha, C. S., Keating, M. J., Murphy, S., Freireich, E. J.
(2000). Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. JCO
18: 547-547
[Abstract][Full Text]
Tsuganezawa, K., Kiyokawa, N., Matsuo, Y., Kitamura, F., Toyama-Sorimachi, N., Kuida, K., Fujimoto, J., Karasuyama, H.
(1998). Flow Cytometric Diagnosis of the Cell Lineage and Developmental Stage of Acute Lymphoblastic Leukemia by Novel Monoclonal Antibodies Specific to Human Pre-B-Cell Receptor. Blood
92: 4317-4324
[Abstract][Full Text]
Dworzak, M. N., Fritsch, G., Froschl, G., Printz, D., Gadner, H.
(1998). Four-Color Flow Cytometric Investigation of Terminal Deoxynucleotidyl Transferase-Positive Lymphoid Precursors in Pediatric Bone Marrow: CD79a Expression Precedes CD19 in Early B-Cell Ontogeny. Blood
92: 3203-3209
[Abstract][Full Text]
Putti, M. C., Rondelli, R., Cocito, M. G., Arico, M., Sainati, L., Conter, V., Guglielmi, C., Cantu-Rajnoldi, A., Consolini, R., Pession, A., Zanesco, L., Masera, G., Biondi, A., Basso, G.
(1998). Expression of Myeloid Markers Lacks Prognostic Impact in Children Treated for Acute Lymphoblastic Leukemia: Italian Experience in AIEOP-ALL 88-91 Studies. Blood
92: 795-801
[Abstract][Full Text]
Uckun, F. M., Sensel, M. G., Sun, L., Steinherz, P. G., Trigg, M. E., Heerema, N. A., Sather, H. N., Reaman, G. H., Gaynon, P. S.
(1998). Biology and Treatment of Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood
91: 735-746
[Full Text]
Borkhardt, A., Cazzaniga, G., Viehmann, S., Valsecchi, M. G., Ludwig, W. D., Burci, L., Mangioni, S., Schrappe, M., Riehm, H., Lampert, F., Basso, G., Masera, G., Harbott, J., Biondi, A.
(1997). Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials. Blood
90: 571-577
[Abstract][Full Text]
Uckun, F. M., Sather, H. N., Gaynon, P. S., Arthur, D. C., Trigg, M. E., Tubergen, D. G., Nachman, J., Steinherz, P. G., Sensel, M. G., Reaman, G. H.
(1997). Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group. Blood
90: 28-35
[Abstract][Full Text]
Borowitz, M. J., Shuster, J., Carroll, A. J., Nash, M., Look, A. T., Camitta, B., Mahoney, D., Lauer, S. J., Pullen, D. J.
(1997). Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study. Blood
89: 3960-3966
[Abstract][Full Text]
Hongo, T., Yajima, S., Sakurai, M., Horikoshi, Y., Hanada, R.
(1997). In Vitro Drug Sensitivity Testing Can Predict Induction Failure and Early Relapse of Childhood Acute Lymphoblastic Leukemia. Blood
89: 2959-2965
[Abstract][Full Text]
Previous
